Last mentioned: Jul 7, 2026
Across the most recent 7 stories covering European Patent Office — 100% positive sentiment, averaging 6.9/10 impact.
This entity profile aggregates every story where the entity meets our minimum relevance threshold before it is linked here — a story naming this entity only in passing, as competitive context for an unrelated subject, does not qualify. That threshold exists because earlier testing surfaced entity pages cluttered with tangential mentions: a story about two unrelated companies merging could otherwise populate a third company's page simply because it was named once for comparison, with no real event of its own. The timeline below reflects genuine milestones and developments specific to this entity, cross-referenced against the same source-verification standard applied to every story on this site. Sentiment measures the directional read of each development for this entity specifically, not the overall tone of the reporting, and impact weights how consequential a development is rather than how widely it was syndicated across outlets.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived. See something wrong on this page? Report a data issue.
Bioequivalence Studies
Projected commencement of studies required for regional regulatory filings.
Strategic Agreement Signed
BioNxt announces a commercialization deal for Cladribine ODF in the Eurasian region.
Patent Grants Confirmed
Patents for the ODF formulation are officially granted in Europe and Eurasia.
MindWalk’s patent application on a biological data layer aims to give any AI model a contextual understanding of biology, promising to speed up drug target identification and clinical research. The move signals a shift toward data-centric healthcare AI.
MindWalk’s European patent application for a high-dimensional biological data architecture could give it a proprietary platform for AI-native pharma R&D. The filing underscores a strategic pivot from model development to data infrastructure.
As AI models become interchangeable, MindWalk filed a European patent on the high-dimensional biological data layer beneath its platform, betting that durable value lies in context, not models. The filing highlights a strategic shift in AI infrastructure.
Source: Pr Newswire · Newswire
The European Patent Office’s grant to SEALSQ for ‘Back-to-Physical’ NFT technology introduces a legally enforceable, hardware-rooted method for proving artwork provenance. The patent, now spanning three jurisdictions, could shift the evidentiary burden in authenticity disputes and set new legal precedents for digital-physical asset linkage.
SEALSQ’s patented semiconductor-based NFT provisioning creates a hardware root of trust that is immune to software exploits, platform shutdowns, and future quantum attacks. WISe.ART’s platform becomes the first cybersecurity-hardened marketplace for physical artwork authentication.
The European patent for hardware-rooted NFTs enables verifiable on-chain provenance for physical artworks, a cornerstone for tokenizing real-world assets. WISe.ART’s platform could catalyze a new wave of liquid, tradeable art-backed tokens in the crypto economy.
Source: The Manila Times · manilatimes.net
BioNxt Solutions has entered a strategic partnership to commercialize its Cladribine Oral Dissolvable Film (ODF) across Eurasia, following successful patent approvals in both Europe and the Eurasian region. This move positions the company to capture market share in the Multiple Sclerosis (MS) treatment space with a novel, patient-friendly delivery mechanism.